Zymeworks Inc. a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It also developed ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.
https://www.zymeworks.com/© 2026 J2T Services Ltd
J2T Services Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by J2T SERVICES LTD.
Registration Number: HE 341520
Address: J2T Services Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
